SeaStar

SeaStar Medical Completes Business Combination with LMF Acquisition Opportunities

Retrieved on: 
Friday, October 28, 2022
Bitcoin, LM, SEC, Company, Form, Acquisition, LinkedIn, Board of directors, Regulation of tobacco by the U.S. Food and Drug Administration, Cytokine, NASDAQ, Private Securities Litigation Reform Act, Forward-looking statement, CEO, Risk, LMAO, Design history file, Association, Food, Inflammation, Foley & Lardner, Patient, AKI, HDE, Industry, SCD, GLOBE, Twitter, FDA, Acute kidney injury, Vii, Failure, CFO, Science, SeaStar, LLP, Solution, Humanitarian Device Exemption, Risk management, Pharmaceutical industry, Nasdaq

DENVER and TAMPA, Fla., Oct. 28, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced that it has completed its previously announced business combination with LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company sponsored by LM Funding America, Inc. (NASDAQ: LMFA). The business combination closed on October 28, 2022.

Key Points: 
  • DENVER and TAMPA, Fla., Oct. 28, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced that it has completed its previously announced business combination with LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company sponsored by LM Funding America, Inc. (NASDAQ: LMFA).
  • Following the closing of the business combination, LMF Acquisition Opportunities, Inc. was renamed SeaStar Medical Holding Corporation and will operate under the same management team as SeaStar Medical, which is led by Eric Schlorff, CEO.
  • Maxim Group LLC served as sole financial advisor and Morgan Lewis & Bockius LLP served as legal counsel to SeaStar Medical in connection with the business combination.
  • These forward-looking statements include, without limitation, SeaStar Medical Holding Corporations, LMAOs and SeaStar Medicals expectations with respect to the proposed business combination between LMAO and SeaStar Medical, including statements regarding the benefits of the transaction, the ability of SeaStar Medical Holding Corporation to achieve value for its stakeholders, the implied valuation of SeaStar Medical, the products offered by SeaStar Medical Holding Corporation and the markets in which it operates, and the expected timing of regulatory approval of SeaStar Medical Holding Corporations products.

LMF Acquisition Opportunities, Inc. Stockholders Approve Previously Announced Business Combination with SeaStar Medical, Inc.

Retrieved on: 
Tuesday, October 18, 2022
Bitcoin, LinkedIn, U.S. Securities and Exchange Commission, XV, 100,000, Sale, Risk, SEC, SEC filing, Science, Xi, Cytokine, SeaStar, NASDAQ, Patient, Association, Twitter, Securities Act of 1933, Inflammation, Nasdaq, Private Securities Litigation Reform Act, Company, Acquisition, Industry, Board, Section 10 of the Canadian Charter of Rights and Freedoms, Form, GLOBE, Special, Prospectus, Forward-looking statement, LMAO, Failure, Suite, Solution, Risk management, Security (finance)

More than 96% of the votes cast at the meeting voted to approve the business combination with SeaStar Medical.

Key Points: 
  • More than 96% of the votes cast at the meeting voted to approve the business combination with SeaStar Medical.
  • Denver-based SeaStar Medical, Inc. is a medical technology company that is focusing on redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs.
  • SeaStar Medicals novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients.
  • LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.

LMF Acquisition Opportunities and SeaStar Medical Announce Effectiveness of Registration Statement and Special Meeting of Stockholders to be Held October 18, 2022 to Approve Business Combination

Retrieved on: 
Wednesday, September 28, 2022
Section 10 of the Canadian Charter of Rights and Freedoms, 100,000, SeaStar, Special, LMAO, Industry, Patient, U.S. Securities and Exchange Commission, Exercise, SEC filing, Xi, NASDAQ, Adoption, Inflammation, Tripura Merger Agreement, Cytokine, Suite, Sale, Acquisition, Person, Science, Prospectus, SEC, Failure, XV, Registration statement, Risk, Forward-looking statement, Telephone, Board, GLOBE, Proxy, Register, Twitter, LinkedIn, Private Securities Litigation Reform Act, Securities Act of 1933, Solution, Form, Holding company, Internet service provider, Risk management, Security (finance), Nasdaq

DENVER and TAMPA, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose acquisition company sponsored by LM Funding America, Inc. (NASDAQ:LMFA), and SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced that LMAO’s registration statement on Form S-4 (“Registration Statement”) related to the two companies’ previously announced business combination was declared effective by the U.S. Securities and Exchange Commission on September 26, 2022.

Key Points: 
  • LMAO commenced mailing to stockholders on September 28, 2022 the definitive proxy statement relating to the special meeting of LMAO stockholders (the Special Meeting).
  • The Special Meeting to approve the pending business combination and other related matters is scheduled for October 18, 2022 at 10:00 a.m. Eastern Time.
  • The Special Meeting will be held at LMAOs office located at 1200 W. Platt St., Suite 100, Tampa, Florida 33606.
  • LMAOs board of directors unanimously recommends that its stockholders vote FOR each of the proposals, including the proposed business combination.

LMF Acquisition Opportunities, Inc. Announces Extension of Deadline to Complete Business Combination

Retrieved on: 
Friday, July 29, 2022
Sale, Section 10 of the Canadian Charter of Rights and Freedoms, SEC filing, Person, Company, LinkedIn, LLC, Acquisition, Cytokine, U.S. Securities and Exchange Commission, Tripura Merger Agreement, Solution, 100,000, Prospectus, GLOBE, Industry, Twitter, SEC, SeaStar, Securities Act of 1933, Failure, Board, Science, Nasdaq, Form, Register, Xi, Forward-looking statement, Registration statement, Private Securities Litigation Reform Act, Risk, NASDAQ, Adoption, LMAO, Inflammation, Extension, Patient, XV, Suite, Risk management, Security (finance)

The Extension provides the Company with additional time to complete its proposed business combination with SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs.

Key Points: 
  • The Extension provides the Company with additional time to complete its proposed business combination with SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs.
  • Denver-based SeaStar Medical is a privately-held medical technology company that is focusing on redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs.
  • SeaStar Medicals novel technologies rely on science and innovation to provide life-saving solutions to critically-ill patients.
  • LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

Skyway Capital Markets Advises SPAC on $85 Million Medical Technology Merger

Retrieved on: 
Monday, May 2, 2022
Biotechnology, Finance, Medical Devices, Health, Professional Services, Board, AKI, Cytokine, M&A, FINRA, Health care, Nasdaq, Acute kidney injury, LLC, Monocyte, Roman Catholic Diocese of La Crosse, Death, LMAO, Manifest and latent functions and dysfunctions, Patient, FDA, Inflammation, End organ damage, Environment, Adult, Capital market, Humanitarian Device Exemption, SPAC, Science, SeaStar, Starfish, SCD, Solution, Neutrophil, SIPC, Technology, CEO, Ownership, Growth, Acquisition, Multimedia, Risk management, Financial services

Skyway Capital Markets, LLC (Skyway) is pleased to announce the merger of SeaStar Medical, Inc. (SeaStar Medical), a medical technology company developing extracorporeal therapies to reduce the consequences of excessive inflammation on vital organs, and LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) (LMAO), a publicly traded special purpose acquisition company.

Key Points: 
  • Skyway Capital Markets, LLC (Skyway) is pleased to announce the merger of SeaStar Medical, Inc. (SeaStar Medical), a medical technology company developing extracorporeal therapies to reduce the consequences of excessive inflammation on vital organs, and LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) (LMAO), a publicly traded special purpose acquisition company.
  • Skyway Capital Markets LLC served as sole financial and valuation advisor to LMAO in connection with the proposed business combination.
  • Skyway Capital Markets LLC served as sole financial and valuation advisor to LMAO in connection with the proposed business combination.
  • Skyway Capital Markets, LLC is a leading M&A advisor to closely held, founder-owned, family-owned middle-market businesses, and select public companies.

SeaStar Medical to Become Publicly Listed on Nasdaq via Business Combination with LMF Acquisition Opportunities, Inc.

Retrieved on: 
Friday, April 22, 2022
Monocyte, 100,000, AKI, Science, SeaStar, GLOBE, Sale, Suite, Patient, Common stock, LinkedIn, Board of directors, End organ damage, Technology, Form, Prospectus, Acute kidney injury, Forward-looking statement, FDA, Acquisition, Securities Act of 1933, COVID-19, Neutrophil, Adoption, U.S. Securities and Exchange Commission, Adult, Annual report, Private Securities Litigation Reform Act, Chief executive officer, Humanitarian Device Exemption, Solution, Tripura Merger Agreement, Cytokine, SCD, Board, XV, Twitter, Failure, Nasdaq, Section 10 of the Canadian Charter of Rights and Freedoms, SEC, Industry, PIPE, Death, Inflammation, Person, Shareholder, Registration statement, Register, Critical care, Manifest and latent functions and dysfunctions, Risk, LMAO, Hospital, Security (finance), Pharmaceutical industry, Risk management

This is a tremendous opportunity to transform patient treatment, said Eric Schlorff, President and Chief Executive Office of SeaStar Medical.

Key Points: 
  • This is a tremendous opportunity to transform patient treatment, said Eric Schlorff, President and Chief Executive Office of SeaStar Medical.
  • The combined company will be known as SeaStar Medical Holding Corporation and will operate under the same management team as SeaStar Medical, which is led by Mr. Schlorff.
  • As part of the transaction, all SeaStar Medical shares owned by SeaStar Medicals existing equity holders will be converted into Class A Common Stock of SeaStar Medical Holding Corporation.
  • Maxim Group LLC served as sole financial advisor to SeaStar Medical in connection with the proposed business combination.

SeaStar Medical Announces Additions to Board of Directors

Retrieved on: 
Monday, January 11, 2021
SeaStar, Rick Grimes

DENVER, Jan. 11, 2021 /PRNewswire/ -- SeaStar Medical, a medical technology company delivering novel therapeutic immunomodulating solutions to improve organ function, announced today it has appointed Rick Barnett and Dr. Allan J. Collins to its board of directors, effective January 8, 2021.

Key Points: 
  • DENVER, Jan. 11, 2021 /PRNewswire/ -- SeaStar Medical, a medical technology company delivering novel therapeutic immunomodulating solutions to improve organ function, announced today it has appointed Rick Barnett and Dr. Allan J. Collins to its board of directors, effective January 8, 2021.
  • "We are excited and honored to welcome Rick and Allan as new independent directors to the SeaStar Medical board, " said Ray Chow, Chair of the Board of Directors of SeaStar Medical.
  • "They join SeaStar Medical at an important time as we transition to commercializing our Selective Cytopheretic (SCD) therapeutic device.
  • "The addition of Allan and Rick to the SeaStar Medical Board of Directors is another important step in advancing our business and clinical strategy.

SeaStar Medical Appoints New Board Chairman To Deliver Growth

Retrieved on: 
Thursday, May 21, 2020
SeaStar, Medical device

DENVER, May 21, 2020 /PRNewswire/ -- SeaStar Medical, a medical device company focused on delivering novel immunomodulating medical device solutions to improve organ function, today announced the appointment of Ray Chow as chairman of its Board of Directors.

Key Points: 
  • DENVER, May 21, 2020 /PRNewswire/ -- SeaStar Medical, a medical device company focused on delivering novel immunomodulating medical device solutions to improve organ function, today announced the appointment of Ray Chow as chairman of its Board of Directors.
  • Ray will lead the Board, working with the existing investors and any future investment groups.
  • In addition, Ray will oversee Business Development and Global Partnership activities for SeaStar Medical.
  • "SeaStar is transforming the industry with a clearly differentiated technology that is helping to save lives," said Eric Schlorff, Chief Executive Officer of SeaStar Medical.

COVID-19 Study from SeaStar Medical Using DSG's eCaseLink 10 Virtual Trial Technologies

Retrieved on: 
Tuesday, May 5, 2020
Software, Practice Management, Health, Medical devices, Data management, Hospitals, Technology, Clinical trials, Food and Drug Administration, United States Public Health Service, SeaStar, Health, Articles, DSG, EmpiriStat

COVID-19 pandemic brings its own unique challenges for investigative sites now overwhelmed with limited or no time to get trained on a study protocol.

Key Points: 
  • COVID-19 pandemic brings its own unique challenges for investigative sites now overwhelmed with limited or no time to get trained on a study protocol.
  • Fast, because doctors at these sites are forced to move at a frenetic pace.
  • eCaseLink provides the fastest start up, quickest database lock, and most rapid FDA submissions resulting in a measurable ROI.
  • We are happy that our partner, EmpiriStat, and an upcoming medical device company like SeaStar Medical chose us to run their trial.

SeaStar Medical Foundation Makes A Splash To Impact Those Affected By Organ Failure

Retrieved on: 
Friday, December 20, 2019
Lifeline, SeaStar, Organ transplantation, Organ procurement organization

DENVER, Dec. 20, 2019 /PRNewswire/ --SeaStar Medical Foundation receives 501(c)(3) Certificate from the IRS, launches mission to accelerate medical discovery in unmet orphan markets.

Key Points: 
  • DENVER, Dec. 20, 2019 /PRNewswire/ --SeaStar Medical Foundation receives 501(c)(3) Certificate from the IRS, launches mission to accelerate medical discovery in unmet orphan markets.
  • Fueled by a sense of urgency, SeaStar Medical Foundation was founded to offer a lifeline for children and adults affected by organ dysfunction and failure by providing financial support to the researchers, clinicians and companies addressing this largely unmet need.
  • SeaStar Medical Foundation aims to increase the number of transplantable organs by working together with the nation's 58 Organ Procurement Organizations supporting available technologies and infrastructures that can be more easily deployed to effectively tackle this critical organ shortage.
  • SeaStar Medical Foundation will also support research and development of medical protocols to treat a variety of conditions and diseases that cause organ damage and failure.